Most bought healthcare stocks in Q1 2026
See which Healthcare stocks institutional investors increased the most in Q1 2026, measured as net growth in reported share positions from Q4 2025 into Q1 2026. Notable additions at the top of this list include PFIZER INC (PFE), MERCK & CO. INC. (MRK), VIATRIS INC (VTRS), MYRIAD GENETICS INC (MYGN). These rankings aggregate SEC 13F filings from all institutional investors in our database.
| Symbol | Name | Net shares | Net value | New | Added | Trimmed | Sold out | Holding now |
|---|---|---|---|---|---|---|---|---|
| PFE | PFIZER INC | 546,850,787 | $24.64B | 244 | 1277 | 1069 | 175 | 2890 |
| MRK | MERCK & CO. INC. | 171,508,093 | $45.66B | 316 | 1410 | 1528 | 127 | 3672 |
| VTRS | VIATRIS INC | 149,857,835 | $2.93B | 131 | 346 | 313 | 96 | 1000 |
| MYGN | MYRIAD GENETICS INC | 128,625,808 | -$6.77M | 32 | 75 | 66 | 49 | 200 |
| IPSC | CENTURY THERAPEUTICS INC | 113,742,557 | $286.64M | 31 | 16 | 10 | 7 | 70 |
| JNJ | JOHNSON & JOHNSON | 110,071,923 | $97.55B | 294 | 1683 | 2104 | 134 | 4543 |
| ABBV | ABBVIE INC | 104,352,483 | $10.72B | 195 | 1685 | 1640 | 186 | 3970 |
| ABT | ABBOTT LABORATORIES | 104,248,457 | -$8.99B | 174 | 1098 | 1396 | 306 | 3030 |
| BMY | BRISTOL-MYERS SQUIBB CO | 87,529,217 | $13.58B | 262 | 1037 | 857 | 152 | 2477 |
| BSX | BOSTON SCIENTIFIC CORP | 86,034,058 | -$31.60B | 189 | 659 | 627 | 277 | 1640 |
| ERAS | ERASCA INC | 77,432,487 | $3.30B | 96 | 76 | 39 | 24 | 222 |
| LXRX | LEXICON PHARMACEUTICALS INC | 74,499,287 | $218.03M | 31 | 39 | 28 | 15 | 134 |
| ELAN | ELANCO ANIMAL HEALTH INC | 71,468,273 | $1.89B | 97 | 192 | 151 | 55 | 509 |
| UNH | UNITEDHEALTH GROUP INC | 70,285,318 | -$15.83B | 187 | 1160 | 1360 | 394 | 2963 |
| ALXO | ALX ONCOLOGY HOLDINGS INC | 66,692,537 | $157.23M | 25 | 18 | 11 | 13 | 68 |
| OCGN | OCUGEN INC | 66,577,740 | $139.88M | 46 | 42 | 22 | 18 | 135 |
| CVS | CVS HEALTH CORP | 63,061,328 | -$3.30B | 154 | 715 | 734 | 199 | 1838 |
| GILD | GILEAD SCIENCES INC | 61,271,018 | $24.58B | 244 | 842 | 876 | 105 | 2279 |
| RXRX | RECURSION PHARMACEUTICALS-A | 57,889,703 | -$100.99M | 59 | 131 | 82 | 47 | 332 |
| CNC | CENTENE CORP | 57,516,617 | -$1.49B | 103 | 301 | 338 | 140 | 849 |
| CTMX | CYTOMX THERAPEUTICS INC | 57,361,077 | $332.88M | 77 | 58 | 27 | 20 | 177 |
| AVTR | AVANTOR INC | 56,479,487 | -$1.65B | 90 | 166 | 124 | 71 | 425 |
| SGMO | SANGAMO THERAPEUTICS INC | 56,466,488 | $5.58M | 27 | 30 | 16 | 16 | 110 |
| BCRX | BIOCRYST PHARMACEUTICALS INC | 56,135,083 | $860.32M | 72 | 114 | 74 | 42 | 296 |
| LLY | ELI LILLY & CO | 55,132,850 | -$45.40B | 233 | 1906 | 1669 | 232 | 4291 |
| GERN | GERON CORP | 48,555,216 | $101.31M | 37 | 90 | 53 | 40 | 252 |
| NEOG | NEOGEN CORP | 48,034,118 | $710.25M | 46 | 103 | 93 | 40 | 304 |
| OVID | OVID THERAPEUTICS INC | 46,264,846 | $139.74M | 29 | 33 | 20 | 10 | 102 |
| CATX | PERSPECTIVE THERAPEUTICS INC | 45,727,175 | $233.71M | 46 | 40 | 28 | 22 | 133 |
| DXCM | DEXCOM INC | 45,284,105 | $1.84B | 148 | 375 | 312 | 93 | 945 |
| MRNA | MODERNA INC | 43,793,417 | $7.68B | 145 | 231 | 195 | 86 | 708 |
| BKD | BROOKDALE SENIOR LIVING INC | 43,563,276 | $1.19B | 76 | 96 | 81 | 26 | 279 |
| RCEL | AVITA MEDICAL INC | 42,912,371 | $59.59M | 25 | 27 | 11 | 15 | 76 |
| WAT | WATERS CORP | 42,378,251 | $8.03B | 457 | 557 | 111 | 83 | 1155 |
| IBRX | IMMUNITYBIO INC | 40,721,373 | $1.04B | 145 | 134 | 60 | 32 | 380 |
| AMGN | AMGEN INC | 39,747,161 | $24.08B | 221 | 1181 | 1228 | 133 | 3079 |
| TALK | TALKSPACE INC | 39,597,756 | $318.50M | 67 | 50 | 42 | 29 | 177 |
| OGN | ORGANON & CO | 39,172,772 | $95.98M | 82 | 134 | 194 | 93 | 597 |
| SHC | SOTERA HEALTH CO | 38,850,959 | -$351.56M | 55 | 146 | 58 | 38 | 291 |
| ALMS | ALUMIS INC | 38,729,459 | $1.51B | 89 | 59 | 33 | 25 | 193 |
| CMPS | COMPASS PATHWAYS PLC | 37,810,631 | $133.29M | 53 | 68 | 25 | 27 | 188 |
| FOLD | AMICUS THERAPEUTICS INC | 37,679,803 | $444.87M | 53 | 107 | 88 | 81 | 293 |
| ESPR | ESPERION THERAPEUTICS INC | 37,424,392 | -$29.01M | 39 | 64 | 60 | 31 | 202 |
| ALHC | ALIGNMENT HEALTHCARE INC | 37,369,434 | $60.25M | 75 | 110 | 74 | 43 | 288 |
| VIR | VIR BIOTECHNOLOGY INC | 35,707,863 | $617.18M | 69 | 116 | 40 | 31 | 249 |
| SABS | SAB BIOTHERAPEUTICS INC | 34,696,832 | $135.85M | 34 | 24 | 6 | 6 | 75 |
| XRAY | DENTSPLY SIRONA INC | 34,169,458 | $424.00M | 75 | 138 | 111 | 50 | 374 |
| RLMD | RELMADA THERAPEUTICS INC | 33,970,520 | $339.15M | 37 | 27 | 24 | 10 | 103 |
| OPK | OPKO HEALTH INC | 33,615,887 | $20.04M | 42 | 58 | 58 | 24 | 227 |
| A | AGILENT TECHNOLOGIES INC | 32,793,071 | -$1.12B | 108 | 391 | 366 | 158 | 1048 |
Frequently asked questions about Most bought healthcare stocks in Q1 2026
What are the most bought Healthcare stocks in Q1 2026?
The most bought healthcare stocks in Q1 2026 are those with the largest increase in reported share counts across institutional investors compared to Q4 2025, based on SEC 13F filings.
Which healthcare stocks did institutional investors added to the most in Q1 2026?
Among filers in this sector, net additions were largest in companies such as PFIZER INC (PFE), MERCK & CO. INC. (MRK), VIATRIS INC (VTRS), based on aggregated 13F data.
How is institutional buying calculated?
Buying is calculated by summing the net increase in shares reported by institutional investors between two consecutive quarterly 13F snapshots (compared to Q4 2025).
Does this include all institutional owners?
Yes. These rankings aggregate SEC 13F filings from all institutional investors in our database, not only the investors we track individually.
Are these trades real-time?
No. 13F filings are reported quarterly and may be delayed by up to 45 days. The data reflects positions at the end of the reporting period, not real-time trading activity.